Building the Business Case for Better RWD: What Clin Ops Leaders Need to Show the C-Suite

Key takeaways: 

• Clin ops leaders often know intuitively that their data foundation is limiting their artificial intelligence (AI) performance. The harder conversation is making that case to executives who approved the AI investment and expect to see results. 

• The business case for better real-world data (RWD) isn’t an argument against the AI investment already made. It’s the argument for why that investment will finally deliver. 

• The evidence base exists. The ROI is quantifiable. What most clin ops leaders lack isn’t the argument. It’s the framing.

This blog series has built a comprehensive case for why data quality determines AI performance, what the right data foundation looks like, how to evaluate whether yours is solid, and what leading organizations have done differently.  

This post addresses a challenge that sits outside the technical and operational conversation but often determines whether any of it gets acted on – the ‘internal selling’ problem. 

Clin ops leaders who have worked through the framework in the earlier posts in this series are often left with a clear diagnosis and an uncertain path to resources. The C-suite approved a significant AI investment. Results have been inconsistent. The argument they need to make is: the investment was right, but it needs a stronger foundation to deliver, and here’s what that investment looks like and what it returns. 

That conversation is genuinely difficult. Here’s a framework for having it. 

Acknowledge the AI Investment Before Arguing for More  

The instinct when making a case for additional investment is to lead with the problem. The AI isn’t performing. The data foundation is weak. The results don’t match the projections. 

That framing asks the executive audience to accept that a previous decision was wrong before they’ve heard the solution. It’s accurate, but it’s not persuasive.  

A more effective entry point is to acknowledge the AI investment as correct and then introduce the data foundation argument as the reason it will pay off. Clinical AI has demonstrated the ability to improve enrollment rates by 65%, cut trial timelines by 30 – 50%, and reduce costs by 40%. Those results are real. They’re being achieved by organizations operating with the right data foundation beneath their AI. The investment your organization made in AI was a bet on that potential. Strengthening the data foundation is what converts the bet into a return.  

This framing doesn’t require anyone to admit a mistake. It requires a refinement, a recognition that the AI layer was right, and the data layer needs to catch up.  

Quantify the Cost of the Current Gap  

Abstract arguments about data quality tend to stall in executive conversations. Quantified arguments about what the current gap is costing tend to move them forward. 

The blog series has provided the evidence base for this calculation. Protocol amendments that could have been avoided with better feasibility data have direct, calculable costs in timeline delays and budget overruns. Recruitment shortfalls that trace to site recommendations misaligned with actual patient availability have measurable impact on study timelines and per-patient costs. Eligibility criteria that are too narrow, the kind of problem that AI operating on comprehensive data has demonstrated the ability to correct by expanding eligible patient pools by 189%, represent a quantifiable constraint on enrollment efficiency.  

The argument isn’t that an underperforming data foundation is expensive in the abstract. It’s that your specific AI investments in protocol design, feasibility, site selection, and recruitment are returning less than they should, and the gap between current performance and demonstrated best-in-class performance has a number attached to it. 

Connect the Data Foundation to the Metrics Executives Already Track 

The executive conversation is most productive when it connects directly to the metrics leadership is already accountable for: cost per patient, cycle time, protocol amendment rates, enrollment against target, and, increasingly, the performance metrics tied to AI investments already made. 

Each of the four pillars of AI-ready data maps to metrics that matter at the executive level:   

• Comprehensiveness drives feasibility accuracy, which drives enrollment against target. 

• Recency drives site selection quality, which drives recruitment conversion and reduces the cost of site non-performance.  

• Quality drives protocol design, which reduces amendment rates and the timeline and budget impact that follows from them.  

• Transparency drives regulatory confidence in real-world evidence, which affects submission timelines and approval risk.

The business case for better RWD isn’t a data architecture discussion. It’s a performance discussion framed in the language of the metrics the organization is already trying to move.  

Frame It as Infrastructure, Not Expense  

Capital allocation conversations move more easily when the investment is framed as infrastructure rather than expense. Expense gets scrutinized against the question of whether it’s necessary. Infrastructure gets evaluated against the question of what it enables. 

The data foundation argument is an infrastructure argument. It’s the case that the AI capabilities already purchased (and the more autonomous AI capabilities the organization will need in the near term) require a specific kind of foundation to perform.  

Organizations that build that foundation now will be able to act on the next generation of AI capabilities from a position of readiness. Organizations that don’t will find themselves in the same conversation again in two years, with a more urgent timeline, higher stakes, and the additional complexity of trying to fix the foundation while autonomous AI systems are already in operation.  

That forward-looking framing, investing now to avoid a much more expensive problem later, tends to land well with executives who are already thinking about where AI in clinical development is heading.  

The Conversation Starts with a Diagnosis 

Before any of this framing can be effective, it needs a specific diagnosis underneath it. The checklist in the third post in this series is designed exactly for this purpose: to give clin ops leaders a structured way to identify where their data foundation is strong and where the gaps are most likely creating drag on AI performance. 

Walking into an executive conversation with a specific diagnosis – here is where our data foundation is creating drag on our AI performance, here is what it’s costing us, and here is what fixing it returns – is meaningfully more effective than walking in with a general argument about data quality. 

The full evidence base for that conversation (the framework, the case studies, and the quantified outcomes) in The Real-World Data Advantage: Why Clinical Operations Teams Are Rethinking AI Strategy. 

About Asad Basir
Asad serves as Vice President of Product at TriNetX, where he leads the development of the company’s product roadmap. He is focused on translating customer needs and market insights into solutions that help life sciences and healthcare organizations unlock the value of real-world data and advance clinical research across the drug development lifecycle.